retatrutide peptide. Triple Agonist (GLP-1/GIP/GCG) Retatrutide Significantly Reduces Visceral Fat

Exenatide extended-release (Bydureon/BCise) carries a boxed warning regarding thyroid C-cell tumors based on rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

However, you may want to speak to your doctor regarding what symptoms you experience, as they can vary from person to person

Stomach paralysis (delayed gastric emptying) identified as an Ozempic symptom (and other GLP-1 medications) could be managed with Biocare

This dysbiotic state, strongly promoted by a HFD, compromises the intestinal mucus layer and weakens tight junction integrity, leading to increased intestinal permeability (leaky gut) (90, 93, 94)

Vomiting that prevents you from keeping fluids down this raises the risk of dehydration and kidney injury